임상 한눈에 보기

• 42건의 ClinicalTrials.gov 임상 기록
• Phase·Status 요약은 enrollment 상위 표본 기준입니다
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• Phase: Phase 3 · Phase 2, Phase 3 · Phase 2
• Status: Approved for marketing · No longer available · Active, not recruiting
• 주요 endpoint: Disease free survival (DFS) in randomization eligible patients with higher risk features (SR-High) or standard risk average (SR-Avg) B-ALL patients based on randomization with addition of blinatumomab · DFS in boys in the SR-favorable subset of SR B-ALL with or without Down syndrome (DS) · DFS for patients with SR-Avg B-ALL who are negative for MRD measured by flow cytometry and HTS at EOI when treated with standard chemotherapy with a treatment duration of 2 years from the start of interim maintenance (IM)1 · regardless of sex · DFS for patients with standard-risk favorable (SR-Fav) B-ALL when treated with a standard chemotherapy regimen
• 핵심: The investigators propose to study an Aflac-AML chemotherapy backbone prospectively to validate its use in all pediatric…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.